Skip to main content
Article thumbnail
Location of Repository

Is there a role for retinoids to treat minimal residual disease in neuroblastoma?

By K K Matthay and C P Reynolds


A variety of pre-clinical and clinical data point toward high drug levels of retinoids being required to achieve optimal efficacy against neuroblastoma. The results of the Kohler trial reported in this issue demonstrate that low-dose 13-cis-RA does not have clinical efficacy against neuroblastoma in a setting of minimal residual disease. A comparison of the Kohler trial with the US CCG trial provides clinical evidence that high-dose levels of retinoids are optimal for treating minimal residual disease in neuroblastoma. The comparison of high-dose and low-dose 13-cis-RA studies in neuroblastoma suggests the intriguing possibility that high dose, pulse schedules of other retinoids could be effective as therapeutic and chemopreventive agents in diseases where low-dose, chronic retinoid administration was not effective. Pre-clinical and perhaps clinical studies of the latter concept should be considered. © 2000 Cancer Research Campaig

Topics: Editorial
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2000). 55: 853–861 Reynolds CP and Lie S
  2. (2000). Clinical trials with the synthetic analogue fenretinide. Ann NY Acad Sci 768: 148–162 1122 KK Matthay and CP Reynolds British Journal of Cancer (2000) 83(9), 1121–1123 ©
  3. (1998). Drug resistance patterns in human neuroblastoma cell lines derived from patients at different phases of therapy.
  4. (1993). Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
  5. (1999). Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines [see comments].
  6. (1991). Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 366: 203–211
  7. (1992). The effects of retinoic acid on the in vitro and in vivo growth of neuroblastoma cells. Laryngoscope 102: 1133–1149

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.